source
- BioNTech's anti-CTLA-4 drug shows survival advantage in advanced squamous lung cancer at WCLCBioNTech, together with partner OncoC4, presented new overall survival data at the World Conference on Lung Cancer in South Korea, joining other companies such as Summit Therapeutics, GSK and Roche…
- Definium's LSD candidate DT120 shows positive Phase 3 results, moving toward FDA submissionDefinium Therapeutics reported positive topline data from its Phase 3 Panorama trial of DT120, an oral LSD formulation for generalized anxiety disorder (GAD). The trial met its primary endpoint, s…